who medicines strategy - libdoc.who.int - World Health Organization
who medicines strategy - libdoc.who.int - World Health Organization who medicines strategy - libdoc.who.int - World Health Organization
WHO MEDICINES STRATEGY 2004-2007 | 100EO 6.3Good practices in medicineregulation and quality assurancesystems to ensure that qualityis maintained in clinical trials,production, supply and distribution,and post-marketing surveillanceRationaleEssential tools (standards, norms, guidelines)and guidance for good regulatory and qualityassurance practices are widely available,but need to be constantly updated. Somegood practice guidelines, such as GMP andGood Clinical Practice (GCP) guidelines, arenormative documents. Others, like GoodRegulatory Practices, may be of more generalnature and oriented to improving the overallperformance of medicines regulatory agencies.Proper implementation of these regulatory andquality assurance tools according to locallyestablished standard operating procedures isessential as a quality management step for properimplementation of regulation, and to ensurethat the medicines used are safe, effective, andof good quality. The success of regulation isdependent not only on the regulators but alsoon the full compliance of those being regulated(manufacturers and distributors).ProgressAdditional guidelines and tools have beendeveloped, such as new GMP training modulesfor validation, water, heating, ventilation, andair conditioning systems. An external qualityassurance assessment scheme for national andregional quality control laboratories has beencontinued in all six WHO regions, involving 36laboratories. In addition, WHO has developed atool for reviewing national medicine regulatorycapacity, including implementation of GMPguidelines. The review is designed to help bothWHO and the concerned national authoritiesto identify priority areas for capacity building,technical advice, and support. This collaborativework has enabled assessments to be carriedout in a number of countries in order to identifyweaknesses in national regulatory authoritiesand action needed to strengthen capacity.The experience accumulated through thiscollaborative work has helped further refine thedata collection tools and the methodology of thereviews.
COMPONENTS OF THE STRATEGY | 101ChallengesThree types of common imbalance have beenidentified in regulatory practice:> much more time is assigned to premarketingassessment than to post-marketingsurveillance> while product registration is considered amajor responsibility by all the drug regulatoryauthorities, the regulation of drug distributionchannels and information does not enjoy thesame level of attention> in many countries, GMP inspection receivesmore attention and resources than inspectionof distribution channels. 54Meeting the challenges 2004-2007Over the next four years WHO will:> promote implementation of good practice byproviding necessary guidelines, tools, andtechnical assistance> continue to help Member States to assessregulatory capacity and improve regulatoryperformance by capacity building> continue to pursue the external qualityassessment scheme for medicines controllaboratories in all six WHO regions.The quality of products in the market is at riskif regulators and those being regulated fail toapply and monitor principles of good practice inproduction, supply and distribution of medicines,and post-marketing surveillance.OUTCOME INDICATORS1999 2003 2007#REPORTING % TARGET#REPORTING % TARGETNo. of countries with basic quality assurance procedures 95/122 78% 80% 111/137 81% 85%
- Page 62 and 63: WHO MEDICINES STRATEGY 2004-2007 |
- Page 64 and 65: WHO MEDICINES STRATEGY 2004-2007 |
- Page 66 and 67: WHO MEDICINES STRATEGY 2004-2007 |
- Page 68 and 69: WHO MEDICINES STRATEGY 2004-2007 |
- Page 70 and 71: WHO MEDICINES STRATEGY 2004-2007 |
- Page 72 and 73: WHO MEDICINES STRATEGY 2004-2007 |
- Page 74 and 75: WHO MEDICINES STRATEGY 2004-2007 |
- Page 76 and 77: WHO MEDICINES STRATEGY 2004-2007 |
- Page 78 and 79: WHO MEDICINES STRATEGY 2004-2007 |
- Page 80 and 81: WHO MEDICINES STRATEGY 2004-2007 |
- Page 82 and 83: WHO MEDICINES STRATEGY 2004-2007 |
- Page 84 and 85: WHO MEDICINES STRATEGY 2004-2007 |
- Page 86 and 87: WHO MEDICINES STRATEGY 2004-2007 |
- Page 88 and 89: WHO MEDICINES STRATEGY 2004-2007 |
- Page 90 and 91: WHO MEDICINES STRATEGY 2004-2007 |
- Page 92 and 93: WHO MEDICINES STRATEGY 2004-2007 |
- Page 94 and 95: WHO MEDICINES STRATEGY 2004-2007 |
- Page 96 and 97: WHO MEDICINES STRATEGY 2004-2007 |
- Page 98 and 99: WHO MEDICINES STRATEGY 2004-2007 |
- Page 100 and 101: WHO MEDICINES STRATEGY 2004-2007 |
- Page 102 and 103: WHO MEDICINES STRATEGY 2004-2007 |
- Page 104 and 105: WHO MEDICINES STRATEGY 2004-2007 |
- Page 106 and 107: WHO MEDICINES STRATEGY 2004-2007 |
- Page 108 and 109: WHO MEDICINES STRATEGY 2004-2007 |
- Page 110 and 111: WHO MEDICINES STRATEGY 2004-2007 |
- Page 114 and 115: WHO MEDICINES STRATEGY 2004-2007 |
- Page 116 and 117: WHO MEDICINES STRATEGY 2004-2007 |
- Page 118 and 119: WHO MEDICINES STRATEGY 2004-2007 |
- Page 120 and 121: WHO MEDICINES STRATEGY 2004-2007 |
- Page 122 and 123: WHO MEDICINES STRATEGY 2004-2007 |
- Page 124 and 125: WHO MEDICINES STRATEGY 2004-2007 |
- Page 126 and 127: WHO MEDICINES STRATEGY 2004-2007 |
- Page 128 and 129: WHO MEDICINES STRATEGY 2004-2007 |
- Page 130 and 131: WHO MEDICINES STRATEGY 2004-2007 |
- Page 132 and 133: WHO MEDICINES STRATEGY 2004-2007 |
- Page 134 and 135: WHO MEDICINES STRATEGY 2004-2007 |
- Page 136 and 137: WHO MEDICINES STRATEGY 2004-2007 |
- Page 138 and 139: WHO MEDICINES STRATEGY 2004-2007 |
- Page 140 and 141: WHO MEDICINES STRATEGY 2004-2007 |
- Page 142 and 143: WHO MEDICINES STRATEGY 2004-2007 |
- Page 144 and 145: WHO MEDICINES STRATEGY 2004-2007 |
- Page 146 and 147: WHO MEDICINES STRATEGY 2004-2007 |
- Page 148 and 149: WHO MEDICINES STRATEGY 2004-2007 |
- Page 150 and 151: WHO MEDICINES STRATEGY 2004-2007 |
- Page 152 and 153: WHO MEDICINES STRATEGY 2004-2007 |
- Page 154 and 155: WHO MEDICINES STRATEGY 2004-2007 |
- Page 157 and 158: REFERENCES
- Page 159 and 160: REFERENCES | 1471Annual report 2000
- Page 161 and 162: REFERENCES | 14912 th Model List of
WHO MEDICINES STRATEGY 2004-2007 | 100EO 6.3Good practices in medicineregulation and quality assurancesystems to ensure that qualityis ma<strong>int</strong>ained in clinical trials,production, supply and distribution,and post-marketing surveillanceRationaleEssential tools (standards, norms, guidelines)and guidance for good regulatory and qualityassurance practices are widely available,but need to be constantly updated. Somegood practice guidelines, such as GMP andGood Clinical Practice (GCP) guidelines, arenormative documents. Others, like GoodRegulatory Practices, may be of more generalnature and oriented to improving the overallperformance of <strong>medicines</strong> regulatory agencies.Proper implementation of these regulatory andquality assurance tools according to locallyestablished standard operating procedures isessential as a quality management step for properimplementation of regulation, and to ensurethat the <strong>medicines</strong> used are safe, effective, andof good quality. The success of regulation isdependent not only on the regulators but alsoon the full compliance of those being regulated(manufacturers and distributors).ProgressAdditional guidelines and tools have beendeveloped, such as new GMP training modulesfor validation, water, heating, ventilation, andair conditioning systems. An external qualityassurance assessment scheme for national andregional quality control laboratories has beencontinued in all six WHO regions, involving 36laboratories. In addition, WHO has developed atool for reviewing national medicine regulatorycapacity, including implementation of GMPguidelines. The review is designed to help bothWHO and the concerned national authoritiesto identify priority areas for capacity building,technical advice, and support. This collaborativework has enabled assessments to be carriedout in a number of countries in order to identifyweaknesses in national regulatory authoritiesand action needed to strengthen capacity.The experience accumulated through thiscollaborative work has helped further refine thedata collection tools and the methodology of thereviews.